As UnitedHealth tumbles, one competitor said they are doing fine

Published 04/17/2025, 11:12 AM
© Reuters.

Investing.com -- UnitedHealth (NYSE:UNH) sent shockwaves throughout the managed care sector Thursday after posting weak first quarter results and lowering its full year guidance.  However, for at least one competitor, it is not a “we” problem but a “you” problem.

Elevance Health Inc (NYSE:ELV) said this morning that it plans to reaffirm its adjusted net income guidance for full year 2025 to be $34.15 to $34.85 per diluted share when it reports results on April 22, 2025.

The update from Elevance followed the UnitedHealth warning, which sent the entire sector into a tailspin.

UnitedHealth said it now sees full year 2025 adjusted EPS of $26-$26.50, well below the consensus of $29.74.

UnitedHealth stated that its Medicare Advantage business experienced a sharp rise in care activity, especially in physician and outpatient services, exceeding expectations for 2025 and aligning with elevated 2024 levels. Additionally, unexpected shifts in Optum Health member profiles and low 2024 engagement from plans exiting markets disrupted reimbursement plans for 2025. These challenges were further compounded by a greater-than-anticipated impact from ongoing Medicare funding cuts affecting complex patients.

Elevance, for its part, said first-quarter results reflected medical cost trends in line with expectations, including within its Medicare Advantage business, where costs remain elevated but consistent with projections and pricing. The company also reaffirmed its full-year 2025 Medicare Advantage membership outlook of 2.2 to 2.25 million members, as previously stated.

Just after 11:00 AM ET, Elevance shares traded down 3%. But recovered from morning losses of nearly 10%.

UnitedHealth shares last traded down 23%. 

Elsewhere in the sector, Humana (NYSE:HUM) is down 8.4%, CVS Health (NYSE:CVS) is down 2.8%, Cigna (NYSE:CI) is flat, Molina Health is down 3.4%, and Centene (NYSE:CNC) is down 2%.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.